Series of setbacks have not caused Orphazyme CEO to consider departing
Even though much has happened in the four months in which Christophe Bourdon has sat in the main seat at Orphazyme, the newly-minted CEO is determined to seek opportunities in NPC. He does not have a lot to say on where he sees himself in a year.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
A lot has happened since Christophe Bourdon was appointed the head of Orphazyme back in early March. In spite of a series of consecutive disappointments, the CEO does not plan to seek other opportunities than the one he currently has as the chief of the Copenhagen-based biotech company, he tells MedWatch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
